Inotiv Financial Statements From 2010 to 2025

NOTV Stock  USD 4.28  0.18  4.04%   
Inotiv financial statements provide useful quarterly and yearly information to potential Inotiv Inc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Inotiv financial statements helps investors assess Inotiv's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Inotiv's valuation are summarized below:
Inotiv Inc does not presently have any fundamental trends for analysis.
Check Inotiv financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inotiv's main balance sheet or income statement drivers, such as , as well as many indicators such as . Inotiv financial statements analysis is a perfect complement when working with Inotiv Valuation or Volatility modules.
  
Check out the analysis of Inotiv Correlation against competitors.

Inotiv Inc Company Return On Equity Analysis

Inotiv's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Inotiv Return On Equity

    
  -0.43  
Most of Inotiv's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inotiv Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Inotiv Inc has a Return On Equity of -0.4315. This is 98.2% lower than that of the Life Sciences Tools & Services sector and 93.54% lower than that of the Health Care industry. The return on equity for all United States stocks is 39.19% higher than that of the company.

Inotiv Inc Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Inotiv's current stock value. Our valuation model uses many indicators to compare Inotiv value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inotiv competition to find correlations between indicators driving Inotiv's intrinsic value. More Info.
Inotiv Inc is regarded fourth in return on equity category among its peers. It is regarded third in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Inotiv by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

About Inotiv Financial Statements

Inotiv investors use historical fundamental indicators, such as Inotiv's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inotiv. Please read more on our technical analysis and fundamental analysis pages.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries and sells analytical instruments to the pharmaceutical development and contract research industries. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana. Inotiv operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 541 people.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Inotiv Stock Analysis

When running Inotiv's price analysis, check to measure Inotiv's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inotiv is operating at the current time. Most of Inotiv's value examination focuses on studying past and present price action to predict the probability of Inotiv's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inotiv's price. Additionally, you may evaluate how the addition of Inotiv to your portfolios can decrease your overall portfolio volatility.